1. Introduction
===============

Agenesis of the dorsal pancreas is a very rare condition involving a congenital malformation wherein either part or the whole of the dorsal pancreas fails to develop. Affected cases are usually asymptomatic or present with a range of conditions, including hyperglycemia, polysplenia, congenital heart defects, tetralogy of Fallot, or pulmonary artery stenosis. Although advances in imaging technologies have increased the frequency of diagnosis of agenesis of the dorsal pancreas in recent decades, the disease remains rare and reports of such cases remain sporadic. Despite the importance of this diagnosis, affected cases are often confirmed incidentally, often in patients who present with abdominal pain, pancreatitis, other gastrointestinal diseases, or complications involving physical or visceral malformation.^\[[@R1]\]^ The existing diabetes literature has not given special attention to this malformation, despite the frequency of hyperglycemia in affected patients. Here, we describe our experience with a case of agenesis of the dorsal pancreas in a young woman.

2. Case presentation
====================

A 23-year-old Chinese woman visited our department because of hyperglycemia that had been detected during a routine school blood test 3 days earlier. The patient denied any history of abdominal pain, chronic diarrhea, dry mouth, polydipsia, polyuria, overeating, and/or emaciation, and had no evidence of gastrointestinal disease, trauma, or history relevant to hyperglycemia. Neither her parents nor her 2 brothers had a significant medical history (including diabetes). The patient provided consent for the publication of this case report and related figures.

Upon physical examination, the patient was found to have a body mass index of 20.8 kg/m^2^, with regular menstrual cycles and no congenital defects. No abnormal signs were observed. The following results were obtained from a laboratory analysis: fasting plasma glucose: 12.29 mmol/L; postprandial 2-hours plasma glucose: 22.3 mmol/L without ketosis; fasting C peptide release test at 0, 0.5, 1, 2, 3 hours: 0.621, 0.878, 0.615, 0.353, and 0.128 ng/mL, respectively (normal range: 1.1--4.4 ng/mL); fructose: 598.13 μmol/L; glycated hemoglobin/HbA1c: 13.4%; random urinary microfilming: 25.4 mg/L; uric acid: 517 μmol/L; triglycerides: 24.27 mmol/L; cholesterol: 15.47 mmol/L. Anti-insulin, anti-islet cell, and antiglutamic acid decarboxylase antibodies were negative, and amylase and lipase levels were normal. Accordingly, the patient was diagnosed with fatty liver, hyperlipidemia, and hyperuricemia.

Magnetic resonance imaging (MRI) revealed the absence of most of the neck, body, and tail of the pancreas (Figs. [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}), and these findings were further confirmed by magnetic resonance angiography (MRA) and diffusion-weighted imaging (DWI). However, the pancreatic head was not enlarged (Figs. [3](#F3){ref-type="fig"} and [4](#F4){ref-type="fig"}). Magnetic resonance cholangiopancreatography (MRCP) revealed the absence of the dorsal pancreatic duct (Fig. [5](#F5){ref-type="fig"}). There was no evidence of chronic pancreatitis or other visceral malformations. Based on these findings, the patient was diagnosed with agenesis of the dorsal pancreas.

![Axial magnetic resonance image depicts the pancreatic head (white arrow), whereas the pancreatic body and tail are not visible.](medi-97-e0046-g001){#F1}

![Coronal magnetic resonance image shows the pancreatic head (white arrow), whereas the pancreatic body and tail are absent.](medi-97-e0046-g002){#F2}

![Enhanced magnetic resonance image shows the pancreatic head with an uncinate process (white arrow), but does not depict the pancreatic body and tail.](medi-97-e0046-g003){#F3}

![Diffusion-weighted imaging (*b*-value: 600) shows only the pancreatic head (white arrow). The pancreatic body and tail are not visible.](medi-97-e0046-g004){#F4}

![Magnetic resonance cholangiopancreatography reveals the absence of the dorsal pancreatic duct (white arrow).](medi-97-e0046-g005){#F5}

Although the patient had no symptoms of diabetes or neurological changes, she exhibited obvious and severe diabetes-related retinal changes (Fig. [6](#F6){ref-type="fig"}). Therefore, insulin replacement therapy at a daily dosage up to 45 U was administered for diabetes treatment. The patient refused a 24-hours urinary protein analysis. Her blood glucose levels improved after insulin therapy and were maintained with intensive insulin therapy (Novolin R with meals and Novolin N at bedtime). She was subsequently referred to the Ophthalmology Department for the treatment of diabetic retinopathy.

![Fundus angiography reveals fluorescence leakage from neovascularization in the binocular optic disc, with no perfusion of the surrounding retina and late macular-like high fluorescence. A diagnosis of binocular diabetic retinopathy (proliferative phase) and macular edema was made.](medi-97-e0046-g006){#F6}

3. Discussion
=============

As noted above, agenesis of the dorsal pancreas, or congenital short pancreas, is a very rare condition. Similarly, reports of this condition are very rare, with fewer than 100 cases described in the literature since the initial report in 1911.^\[[@R2],[@R3]\]^

The exact etiology of agenesis of the dorsal pancreas remains unknown. During gastrulation, epiblast stem cells differentiate into the ectoderm, endoderm, and mesoderm. The pancreas develops etymologically from the endoderm into dorsal and ventral buds on opposite sides of the foregut. The ventral bud differentiates into the posterior part of the pancreatic head, while the dorsal bud forms the pancreatic tail and body. Fusion of the 2 buds occurs during the seventh week of gestation, followed by growth of the pancreatic ductal system.^\[[@R4]\]^ Autosomal dominant or X-linked dominant inheritance may contribute to this condition, and Rittenhouse and colleagues suggest the involvement of alterations in some retinoic acid and hedgehog signaling pathways.^\[[@R4]\]^

Agenesis of the dorsal pancreas may be asymptomatic, although abdominal pain. In such cases, recurrent pain may be attributable to a lack of papillary muscles or to simultaneous acute or chronic pancreatitis,^\[[@R5]\]^ which may itself be caused by sphincter of Oddi dysfunction, compensatory enzyme hypersecretion, remaining ventral gland hypertrophy, and elevated pancreatic intra-ductal pressure.^\[[@R6]\]^ However, the patient in the present case did not report abdominal pain.

Agenesis of the dorsal pancreas is often reported in combination with other anomalies such as polysplenia syndrome, congenital heart defects (e.g., septal defects), tetralogy of Fallot, or pulmonary artery stenosis,^\[[@R7]\]^ although no such deformity was observed in the present case. Additionally, approximately 50% of patients with this disorder present with hyperglycemia consequent to the lack of islets and beta-cells, which are located in the dorsal pancreas and respond positively to glucose stimulation.^\[[@R1]\]^ Although the patient in this case presented with hyperglycemia, the circumstances were unusual. Notably, the severity of diabetic retinopathy observed at the time of diagnosis suggested a long course of diabetes. However, the patient did not exhibit obvious symptoms and signs. Additionally, although the patient\'s poor level of beta-cell function would suggest type 1 diabetes, tests for diabetes-related autoantibodies were all negative and no history of a DKA attack was reported. Accordingly, these data do not support autoimmune diabetes. Furthermore, the high insulin dosage required to control her glucose level is consistent with an insulin shortage caused by a loss of pancreatic tissue. We further note that the patient preferred a highly caloric diet, which may have led to the conditions of fatty liver, a high uric acid level, and hyperlipidemia, eventual insulin resistance, and accelerated diabetes development. Insulin treatment reduced her uric acid and lipid levels to within normal ranges.

Imaging modalities are useful for the diagnosis of agenesis of the dorsal pancreas. Both MR and CT imaging can facilitate diagnosis and differentiate this condition from other disorders such as carcinoma of the pancreatic head with secondary atrophy of the distal body and tail, pancreatic lipomatosis (i.e., fat replacement of the pancreatic parenchyma), autodigestion secondary to chronic pancreatitis, and pancreatic divisum.^\[[@R8]\]^ DWI and MRA are particularly useful for clarifying pancreatic deformity. Furthermore, both endoscopic retrograde pancreatography (ERCP) and MRCP can be used to confirm the missing dorsal pancreatic duct.^\[[@R3]\]^ However, MRCP, which is noninvasive, should be recommended first because ERCP may induce acute pancreatitis and would thus exacerbate diabetes. In terms of medical costs, however, MR or CT imaging should be sufficient to detect agenesis of the dorsal pancreas. We note that the diagnostic usefulness of ultrasound imaging is limited because interference from bowel gas restricts the ability to visualize the pancreatic body and tail.

4. Conclusion
=============

Most cases of agenesis of the dorsal pancreas involve abdominal pain and/or pancreatitis and are thus detected in Departments of General Surgery and Gastroenterology. By contrast, few cases are detected in the Department of Endocrinology and Metabolism consequent to hyperglycemia. Therefore, we recommend that clinicians consider agenesis of the dorsal pancreas when a young patient is diagnosed with diabetes against a history of other congenital anomalies or in the presence of obvious diabetes-related complications (renal, retinal, or neurological) inconsistent with the course of the disease. We further recommend the inclusion of CT or MR imaging in routine examinations of young patients with diabetes.
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Abbreviations: CT = computed tomography, DWI = diffusion-weighted imaging, ERCP = endoscopic retrograde pancreatography, MR = magnetic resonance, MRA = magnetic resonance angiography, MRCP = magnetic resonance cholangiopancreatography.
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